After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. This time, the AbbVie and Boehringer Ingelheim-partnered biologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback